Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. reports a strong 2025 with rapid growth and first-time profitability driven by its global oncology franchise. The company generated approximately $5.3 billion in total global revenue in 2025, up about 40.2% year over year, and produced net income of $286.9 million.
Operations generated $1.1 billion of net cash from operating activities and free cash flow of $941.7 million, supporting a year-end balance of $4.5 billion in cash and cash equivalents and $1.0 billion of debt. Product revenue grew 39.8% from 2024.
Growth is led by oncology blockbusters BRUKINSA, a BTK inhibitor with about $3.9 billion in 2025 sales and approvals in over 75 markets, and PD‑1 antibody TEVIMBRA, which is approved in more than 50 markets and broadly listed on China’s NRDL. The company is building a “foundational” chronic lymphocytic leukemia franchise around BRUKINSA, BCL2 inhibitor sonrotoclax, and BTK degrader BGB‑16673, while advancing a deep solid-tumor pipeline and over 70 preclinical programs.
BeOne Medicines delivered a strong 2025, with total revenue rising 40% to $5.34 billion and fourth-quarter revenue up 33% to $1.50 billion. Product revenue made up 99% of the total.
Flagship BTK inhibitor BRUKINSA generated $3.9 billion in 2025 sales, up 49%, including $2.8 billion in the U.S. TEVIMBRA added $737 million, up 19%, while Amgen in-licensed products contributed $486 million, up 33%.
GAAP net income improved to $286.9 million from a $644.8 million loss, and free cash flow reached $941.7 million. For 2026, BeOne guides total revenue to $6.2–$6.4 billion, GAAP operating income of $700–$800 million, and non-GAAP operating income of $1.4–$1.5 billion, with gross margin expected in the high-80% range.
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry reported option exercises and share sales. On 02/04/2026, Henry exercised three employee share options covering 6,526, 8,606 and 6,448 ordinary shares, which relate to American Depositary Shares (each ADS represents 13 ordinary shares).
On the same date, Henry sold 664 ADS at $348.79 and 996 ADS at $350.00 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, leaving no ADS directly held. Henry continues to directly hold 223,106 ordinary shares and significant remaining options that vest over multi-year schedules, subject to continued service and potential accelerated vesting on certain termination events.
ONC has a shareholder filing a notice to sell 4,676 American Depositary Shares (ADS). The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value listed as 1,619,672.88.
The ADS were acquired on 02/04/2026 through an exercise of stock options, paid in cash on the same date. The filing also lists recent Rule 10b5-1 sales for Chan Lee, including 996 ADS sold on 11/12/2025 for 347,770.00. The seller represents they are not aware of any undisclosed material adverse information about ONC.
BeOne Medicines Ltd. insider Lee Chan Henry, SVP and General Counsel, reported option exercises and an automatic sale of American Depositary Shares (ADS). On January 7, 2026, Henry exercised three share options covering 2,626, 3,458 and 2,548 Ordinary Shares at exercise prices of $14.96, $16.41 and $12.23 per Ordinary Share. These exercises resulted in issuances of 202, 266 and 196 ADS at prices of $194.47, $213.32 and $159.03 per ADS. The filing also reports a sale of 664 ADS at $331.76 per ADS, carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, Henry reported 223,106 Ordinary Shares beneficially owned directly and continued holdings of multiple option grants with staggered vesting schedules.
BeOne Medicines Ltd. reported that its President and Global Head of R&D received a large equity award in the form of restricted share units. On December 31, 2025, the executive acquired 427,895 ordinary shares at a stated price of $0, reflecting the vesting terms of these units rather than a cash purchase.
After this transaction, the executive beneficially owns 1,451,424 ordinary shares directly and 601,965 shares indirectly through Wang Holdings LLC. The filing also explains a separate RMB Shares Employee Participation Plan tied to the company’s STAR Market offering in China, under which the plan purchased 2,069,546 RMB Shares at an initial public offering price of RMB192.6 per share. The reporting person contributed RMB10 million to this plan and may have an indirect economic interest in some of these RMB Shares while disclaiming beneficial ownership except for any pecuniary interest.
BeOne Medicines Ltd. has fully repaid and terminated a major credit facility with China Merchants Bank Co., Ltd. The company used a portion of the borrowings from its previously disclosed Facilities Agreement, arranged with The Hongkong and Shanghai Banking Corporation Limited and other lenders, to pay off all outstanding amounts under the prior CMB Credit Facility.
As part of this repayment, all commitments by China Merchants Bank to extend further credit, as well as all guarantees and security interests granted by BeOne Medicines under the CMB Credit Facility, were terminated. The company incurred no termination penalties in connection with ending this facility.
BeOne Medicines Ltd. appointed Dr. Lai Wang as President, Global Head of Research and Development, effective January 1, 2026. In this expanded role, he will lead research and development as well as other functions, including business development and alliance management.
Dr. Wang, age 48, has led the Company’s R&D since April 2021 after joining in 2011, and previously served as Director of Research at Joyant Pharmaceuticals. His new compensation includes a $750,000 annual salary, an annual target bonus equal to 75% of base salary, and a one-time equity incentive of $10,000,000 in restricted share units vesting in four equal annual installments, with certain accelerated vesting rights under his employment agreement. The Company states there are no related-party or other arrangements connected to his appointment.
BeOne Medicines Ltd. chief executive officer and director reported sales of American Depositary Shares in mid-December 2025 under a pre-arranged Rule 10b5-1 trading plan.
The Form 4 discloses multiple sales of American Depositary Shares on 12/15/2025 and 12/16/2025 at weighted average prices listed in the report, with each American Depositary Share representing 13 ordinary shares. Following these transactions, the reporting person holds 0 American Depositary Shares directly but continues to beneficially own 5,141,041 ordinary shares directly and additional ordinary shares through various trusts and entities, with certain indirect interests expressly disclaimed as beneficial ownership.
BeOne Medicines Ltd. executive SVP and General Counsel reported stock transactions in the company’s American Depositary Shares (ADSs). On December 10 and 11, 2025, the insider exercised stock options and then sold shares, as shown in the Form 4 tables. The filing shows multiple option exercises into ADSs, followed by open-market sales of 332 ADSs at $318.28 on December 10 and 332 ADSs at $325.00 on December 11.
Each ADS represents 13 ordinary shares, and the derivative securities are stock options with exercise prices of $14.96, $16.41, and $12.23 per ordinary share. The options vest over four-year schedules with initial 25% vesting and the remainder in monthly installments, with potential accelerated vesting upon certain termination events. The sale transactions were carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025.